Veracyte, Inc. (VCYT): one to watch?

Interesting — this was a beat-and-raise quarter, but the stock fell anyway on reimbursement doubts for new tests, so wait for clarity.

👀 WATCH Fundamentals67/100

Fell 21% in 7 trading day(s) — now $47.22

Why VCYT dropped

Veracyte actually reported strong Q2 2026 results and raised full-year guidance, yet the stock sank because investors are worried about unresolved Medicare reimbursement for its new Prosigna test and a small cut to Decipher volume guidance in a low-risk segment.

Fwd P/E 24.2Op margin 15.3%Rev growth 15.5%Debt/equity 2.9%Analyst upside 22.4%

How this scored 67/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 20.4%

✅ Generates cash Free cash flow $106M

✅ Not drowning in debt Debt/equity 2.9% (limit 200%)

✅ Can pay its bills Current ratio 9.2 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 15/25

Operating margin 15.3% 6/9

Net profit margin 20.4% 8/8

Return on equity 8.8% 2/8

Growth Is it getting bigger, or dying? 17/25

Revenue growth 15.5% 6/9

Earnings growth unknown 2/8

Expected profit change 39.2% 8/8

Value Is it cheap right now? 10/25

Forward P/E 24.2 5/10

PEG ratio unknown 2/8

Analyst target upside 22.4% 3/7

Balance sheet Will it survive? 25/25

Debt / equity 2.9% 10/10

Current ratio 9.2 8/8

Free cash flow $106M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for VCYT — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-10. Research only — not financial advice.